CP60 Stock Overview
Develops, manufactures, and markets contact lens wearers. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
CP60 passed our risk checks.
The Cooper Companies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$93.65 |
| 52 Week High | US$101.00 |
| 52 Week Low | US$75.38 |
| Beta | 0.99 |
| 11 Month Change | -5.83% |
| 3 Month Change | 12.22% |
| 1 Year Change | 19.68% |
| 33 Year Change | 4.99% |
| 5 Year Change | 35.72% |
| Change since IPO | 5,991.06% |
Recent News & Updates
Recent updates
Shareholder Returns
| CP60 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -2.0% | -3.4% | -0.2% |
| 1Y | 19.7% | -4.3% | 8.3% |
Return vs Industry: CP60 exceeded the German Medical Equipment industry which returned -3.2% over the past year.
Return vs Market: CP60 exceeded the German Market which returned 9.6% over the past year.
Price Volatility
| CP60 volatility | |
|---|---|
| CP60 Average Weekly Movement | 3.8% |
| Medical Equipment Industry Average Movement | 5.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CP60 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: CP60's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1958 | 15,000 | Al White | www.coopercos.com |
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.
The Cooper Companies, Inc. Fundamentals Summary
| CP60 fundamental statistics | |
|---|---|
| Market cap | €18.89b |
| Earnings (TTM) | €341.30m |
| Revenue (TTM) | €3.61b |
55.2x
P/E Ratio5.2x
P/S RatioIs CP60 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CP60 income statement (TTM) | |
|---|---|
| Revenue | US$3.80b |
| Cost of Revenue | US$1.28b |
| Gross Profit | US$2.52b |
| Other Expenses | US$2.17b |
| Earnings | US$359.30m |
Last Reported Earnings
Jul 31, 2024
Next Earnings Date
Dec 05, 2024
| Earnings per share (EPS) | 1.80 |
| Gross Margin | 66.36% |
| Net Profit Margin | 9.45% |
| Debt/Equity Ratio | 33.2% |
How did CP60 perform over the long term?
See historical performance and comparison